Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380068 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT00380068: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00380068 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 224 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380068, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00380068 record still lists
NCT00380068 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00380068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380068 about?
NCT00380068 is a clinical study titled "Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension". The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertens...
What is the current status of trial NCT00380068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2006-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00380068?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00380068?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00380068's enrollment target sits among peer trials
224 1317th of 2000 higher than 684 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia